TLR3 and breast cancer: After gating out doublet cells and 7-AAD+ cells (Figure 4a), expression of CD40, CD86 and MHC-II on BC-treated D1DCs was measured and compared with D1DCs treated with poly (I:C) (TLR3-Ligand, positive control).